PredictMedix Inc. said it will be "hyper-focused" on commercialization throughout 2023 with plans to secure high-revenue recurring placements for workplaces in industries such as mining, manufacturing, warehousing, construction and other sectors where employee health and safety is of high priority.
In a corporate update, Predictmedix chief operating officer Rahul Kushwah said the company was committed to scaling its Safe Entry stations, which use AI and multispectral cameras to detect health issues, in 2023.
“To this end, the company is currently engaged in discussions with a number of large enterprises for potential commercial deployments,” Kushwah said.
READ: Predictmedix deploys its Safe Entry screening system at LongArm Engineering's Texas facility
He also outlined milestones achieved by the company during 2022, including physical upgrades to the camera units, sensors and chips on Safe Entry and the publication of four peer-reviewed articles in scientific publications.
“Our peer-reviewed publications in scientific journals are crucial in our commercialization plan as it adds credibility and validation for our Fit for Duty screening technology and also gives our customers confidence in using Safe Entry as a complete workplace solution for health and safety screening,” Kushwah said.
“With our strong technological pipeline, we believe Predictmedix is at a commercial-ready stage and able to meet the demand for Safe Entry's Fit for Duty solutions from our prospective customers.”
The full corporate update can be found here.
PredictMedix is an emerging global provider of rapid health screening and remote patient care solutions. The company's Safe Entry Stations, powered by a proprietary artificial intelligence (AI), use multispectral cameras to analyze physiological data patterns and predict various health issues including infectious diseases such as COVID-19 and impairment by drugs, alcohol, or fatigue.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie